

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
25 May 2023 (25.05.2023)



(10) International Publication Number  
**WO 2023/091137 A1**

(51) International Patent Classification:

*A61K 39/395* (2006.01) *A61P 35/04* (2006.01)  
*A61P 35/00* (2006.01) *G01N 33/569* (2006.01)

(21) International Application Number:

PCT/US2021/059975

(22) International Filing Date:

18 November 2021 (18.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicant: **AVEO PHARMACEUTICALS, INC.**  
[US/US]; 30 Winter Street, Boston, Massachusetts 02108  
(US).

(72) Inventor: **BAUMAN, Julie E.**; 1515 N. Campbell Ave.,  
Tucson, Arizona 85724 (US).

(74) Agent: **KOMM, Crystal et al.**; Goodwin Procter LLP, 100  
Northern Avenue/IP Docketing 7th fl, Boston, Massachu-  
setts 02210 (US).

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,  
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

Published:


— with international search report (Art. 21(3))

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,  
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

(54) Title: COMBINATION THERAPY FOR TREATMENT OF CANCER

FIG. 1

• Study Schema:



(57) Abstract: The present invention provides improved methods of treating subjects with cancers, such as head and neck squamous cell carcinoma (HNSCC). In one aspect, the invention provides a method of treating cancer in a subject in need thereof. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of an HGF inhibitor and an EGFR inhibitor. In some embodiments, recurrent or metastatic HNSCC is treated with a combination of ficlalizumab and cetuximab.

WO 2023/091137 A1